Last Updated on:
Lyphe Dispensary has announced the extension of its Noidecs V collection, an affordable and premium-quality medical cannabis range developed in direct response to patient demand.
Building on the successful debut of Noidecs Vital Platinum OG in June 2024, the collection now features four additional products, offering patients a simplified selection process. The Noidecs VOne-VFour line, previously known as Vital, introduces four distinct options: VOne, VTwo, VThree, and VFour, each offering carefully calibrated THC levels.
VOne delivers the lowest THC content, ideal for those new to cannabis or seeking mild relief. THC levels increase progressively across the range, with VFour offering the highest concentration for experienced users, ensuring patients can easily match the product to their specific needs—all at an accessible price point.
“Patients are advocating for lower cost, yet sustainable options, and we want them to know that Lyphe is not only listening but taking action,” said Hayley Thompson, Managing Director at Lyphe Clinic. “The Noidecs VOne-VFour line aims to bridge the gap between quality and cost, offering patients a reliable and accessible option for managing their health conditions.”
Lyphe’s approach combines affordability with freshness and consistent quality, made possible by a streamlined supply chain and scaling efficiencies. The Noidecs V collection reflects the company’s dedication to addressing patient needs without compromising standards.
While VThree marks an exciting addition, regulatory changes by the MHRA will result in adjustments to the branding of “Vital,” though the underlying philosophy remains intact.
Noidecs VThree launches in Winter 2024, with the rest of the collection arriving in early 2025. Updates on availability will be announced soon.
